Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression.

T-cell immunotherapies are rapidly gaining grounds in clinical success. Presently, there is first-to-market knowledge on the translation of research scale methods to clinical and commercial scales. Improved understanding can lead to more consistent and efficient production, scaling, and eventual potency.